648906-06-3

Basic information

• Product Name: 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol
• Synonyms: 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol
• CAS NO: 648906-06-3
• Molecular Weight: 537.701
• Mol File: 648906-06-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol(648906-06-3)
• EPA Substance Registry System: 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol(648906-06-3)

Safety Data

• Hazardous Substances Data: 648906-06-3(Hazardous Substances Data)

Upstream product

• 90560-10-4 6-methoxy-benzo[b]thiophene 
• 19301-39-4 1-benzothiophen-6-ol 
• 648905-98-0 1-{2-[4-(6-benzyloxy-2-bromo-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 648906-04-1 1-{2-[4-(6-benzyloxy-2-bromo-1-oxo-1H-1λ⁴-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 648906-03-0 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 1-oxide 
• 648906-02-9 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 
• 648906-01-8 2,3-dibromo-benzo[b]thiophen-6-ol 
• 648906-00-7 2,2-dimethyl-propionic acid 2,3-dibromo-benzo[b]thiophen-6-yl ester 
• 648905-99-1 2,2-dimethyl-propionic acid benzo[b]thiophen-6-yl ester 
• 648906-05-2 1-(2-{4-[6-benzyloxy-2-(4-ethanesulfonyl-phenyl)-benzo[b]thiophen-3-yloxy]-phenoxy}-ethyl)-piperidine 

Downstream Products

• 648906-07-4 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol hydrochloride 

Relevant articles and documents

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.